Major joint replacement surgery may become safer for patients using diabetes and weight-loss medications like semaglutide and liraglutide. This finding challenges growing concerns about surgical risks from these increasingly popular treatments, potentially reshaping preoperative planning for millions of Americans facing hip and knee replacements.
Analysis of 346,899 patients across 13 studies reveals that those taking GLP-1 receptor agonists experienced 25% fewer infections after knee replacement and 24% fewer revision surgeries after hip replacement within 90 days. Hospital readmission rates also dropped significantly for both procedures. The protective effects appeared consistent across different patient populations and surgical centers, suggesting the benefits extend beyond simple weight loss or blood sugar control.
These results provide crucial real-world evidence as GLP-1 medications like Ozempic and Wegovy reach record prescription levels. Previous theoretical concerns about delayed gastric emptying and aspiration risk during anesthesia have dominated surgical discussions, leading some surgeons to recommend stopping these medications before major operations. However, this meta-analysis suggests the metabolic benefits—improved insulin sensitivity, reduced inflammation, and better wound healing—may outweigh theoretical risks in joint replacement patients.
The findings represent observational data rather than controlled trials, meaning definitive causal relationships remain unproven. Patient selection bias could influence results, as those prescribed GLP-1 agonists might receive more intensive preoperative optimization. Additionally, most included studies had relatively short follow-up periods, leaving questions about long-term outcomes. Still, the consistency across nearly 350,000 patients provides compelling evidence that these medications may enhance rather than compromise surgical outcomes in orthopedic procedures.